Breaking News
November 22, 2018 - Response to daily stressors plays important role in cognitive health of older adults
November 22, 2018 - Efficient method for producing induced pluripotent stem cells
November 22, 2018 - Report outlines inequalities in access to healthcare
November 22, 2018 - New research center will pave way to better diagnosis and treatment of skin diseases
November 22, 2018 - Mylan Initiates Voluntary Nationwide Recall of 15 Lots of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient
November 22, 2018 - Lung Cancer Tumor Markers: MedlinePlus Lab Test Information
November 22, 2018 - Patchy distribution of joint inflammation resolved
November 22, 2018 - Researchers find crucial inhibitory role for signal peptide in GluK1 trafficking
November 22, 2018 - nutritional supplement, could slow some cancers
November 22, 2018 - Researchers awarded $7 million funding in Pancreatic Cancer Collective’s ‘New Therapies Challenge’
November 22, 2018 - UMN researchers focus on improving dermatologic care for sexual and gender minority patients
November 22, 2018 - Researchers harness visible light to develop safer building block for drug discovery
November 22, 2018 - Scientists identify key protein involved in Hantavirus Pulmonary Syndrome
November 22, 2018 - ACAAI: Oral Immunotherapy Is Protective in Peanut Allergy
November 22, 2018 - Arthritis and depression often occur together in older adults
November 22, 2018 - Scientists uncover unexpected ‘foreign’ genes in tiny itch-inducing chigger mite
November 22, 2018 - Negative social cues on tobacco packaging could help reduce smoking intentions
November 22, 2018 - Study finds no differences in quit rates for ‘dual users’ of both traditional and electronic cigarettes
November 22, 2018 - Immunity connects gut microbiota and age-related pathologies
November 22, 2018 - New diagnostics based on nanopore analytics and AI can identify single influenza virions
November 22, 2018 - Blocking activity of plasma protein can be possible way to protect against radiation-induced injury
November 22, 2018 - Secondhand Pot Smoke Found in Kids’ Lungs
November 22, 2018 - Air pollution may be linked to heightened dementia risk
November 22, 2018 - Brain implant lets people with limb paralysis compose and send emails, select videos and even play music, just by thinking
November 22, 2018 - Should health-care workers press charges against violent patients?
November 22, 2018 - Obesity linked to COPD in never-smokers
November 22, 2018 - Improving dementia treatment and staff training in care homes saves thousands of pounds per year
November 22, 2018 - Researchers identify genetic changes that could increase risk for death by suicide
November 22, 2018 - John Snow Labs launches new Data Market to help healthcare and life science innovators
November 22, 2018 - New inhibitor could hold key to treating Acute Respiratory Distress Syndrome
November 22, 2018 - Misconceptions about opioid use undermine pain control among Asian cancer patients
November 22, 2018 - Owlstone Medical named Medtech Company of the Year
November 22, 2018 - Anabolic steroids may increase risk of early death in men
November 22, 2018 - Researchers develop model that predicts transmissibility of viral zoonoses
November 22, 2018 - Evidence mounts that an eye scan may detect early Alzheimer’s disease
November 22, 2018 - Sensors could provide dexterity to robots, with potential surgical applications
November 22, 2018 - Why Are We Still So Fat?
November 22, 2018 - MRI scans may help predict dementia risk
November 22, 2018 - Groundbreaking research projects show how AI can be used to predict under diagnosed chronic diseases
November 21, 2018 - Stand Up to Cancer supports potential approach to more efficiently target pancreatic cancer
November 21, 2018 - Using smartphone confocal microscopes to stop cancer
November 21, 2018 - Self-care program for COPD patients reduces emergency room visits and burdensome symptoms
November 21, 2018 - Blueprint Medicines Announces Updated NAVIGATOR Trial Results in Patients with Advanced Gastrointestinal Stromal Tumors Supporting Development of Avapritinib Across All Lines of Therapy
November 21, 2018 - Cocaine adulterant may cause brain damage
November 21, 2018 - Amid the devastation, a Stanford doctor stitches up George, a search dog
November 21, 2018 - America’s Health-Care System Is Making the Opioid Crisis Worse
November 21, 2018 - Colorectal cancer screening reduces need for intense treatments among male patients
November 21, 2018 - Scientists find evidence of prions in the eyes of CJD patients
November 21, 2018 - Study explores individual and organizational risk factors for one-year mortality in ICU survivors
November 21, 2018 - Pulmonologists want more information on inhalation devices for COPD
November 21, 2018 - Cessation fatigue predicts relapse rate after attempts to quit smoking
November 21, 2018 - Special care should be taken with drugs that inhibit epigenetic factors, study suggests
November 21, 2018 - More than one in ten heavy cannabis users experience withdrawal after quitting cannabis
November 21, 2018 - Reflections on the California fires
November 21, 2018 - Donna Lynne Appointed to Key Leadership Role at CUIMC
November 21, 2018 - Smoke-free laws associated with reduced systolic blood pressure
November 21, 2018 - Achieving new guideline blood pressure goals may prevent 3 million cardiovascular events
November 21, 2018 - LDR brachytherapy for treating early-stage prostate cancer lacks conclusive data
November 21, 2018 - Older adults with CVD more likely to experience rapid functional decline
November 21, 2018 - Purified omega-3 and aspirin reduce pre-cancerous bowel polyps, shows study
November 21, 2018 - Study warns that potential epigenetic therapy may boost lung cancer stem cells
November 21, 2018 - Noise pollution in hospital impact quality and safety of healthcare
November 21, 2018 - Interventions to improve sleep may reduce risk of falls
November 21, 2018 - Outdoor air pollution linked to intellectual disabilities in children
November 21, 2018 - Study highlights need for better screening tools to detect maternal sepsis
November 21, 2018 - Higher Risk for Amputation, DKA With SGLT2 Inhibitors for T2DM
November 21, 2018 - Researchers stop ‘sneaky’ cancer cells in their tracks
November 21, 2018 - People who are afraid to draw their blood over-estimate the risk of fainting
November 21, 2018 - Personalized physical exercise reverses functional, cognitive deterioration in the elderly
November 21, 2018 - COPD linked to obesity in older women who have never smoked
November 21, 2018 - AHA: Cold-Weather Drinks Are Here, But Watch Out for the Calories
November 21, 2018 - Crowds line up at 1st East Coast pot shops
November 21, 2018 - Merck declares 2018 Life Science Award winners
November 21, 2018 - Many people underestimate the impact of sprains, say foot scientists
November 21, 2018 - Lower levels of protein make squamous carcinoma cells more invasive
November 21, 2018 - Study highlights a new predictor of type 2 diabetes
November 21, 2018 - NTU and TTSH join forces to improve doctor-patient communication
November 21, 2018 - New low-cost injectable hydrogel could help wounds heal faster
November 21, 2018 - Merck Announces Winners of 2018 Life Science Awards
November 21, 2018 - Check your medical records for dangerous errors
Acer Therapeutics Submits NDA for Edsivo (celiprolol) for the Treatment of Vascular Ehlers-Danlos syndrome (vEDS)

Acer Therapeutics Submits NDA for Edsivo (celiprolol) for the Treatment of Vascular Ehlers-Danlos syndrome (vEDS)

image_pdfDownload PDFimage_print

Treatment for Vascular Ehlers-Danlos Syndrome

Acer Therapeutics Submits NDA for Edsivo (celiprolol) for the Treatment of Vascular Ehlers-Danlos syndrome (vEDS)

NEWTON, MA – October 29, 2018 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Edsivo for the treatment of vascular Ehlers-Danlos syndrome (vEDS). Pursuant to the Prescription Drug User Fee Act (PDUFA), the FDA has 60 days to determine whether to accept the submission for review. Along with the NDA submission, Acer has requested Priority Review, which if granted, could result in a six-month review period. Priority Review is a designation given to drugs that offer a significant improvement in treatment or provide treatment where no satisfactory alternative therapy exists.

“Our NDA submission represents the culmination of extensive efforts of our employees, investigators, clinical trial sites, contract research organizations, caregivers and patients,” said William Andrews, M.D., FACP, Chief Medical Officer of Acer. “We now look forward to continuing to work with the FDA as they review our NDA, with hopes to make Edsivo available as quickly as possible in the U.S. We are grateful to the vEDS patient and advocacy community for their continued involvement, support and feedback as we work together to advance Edsivo, which has the potential to be a significant step forward in the care of patients with this devastating disease.”

About Edsivo and vEDS

Ehlers-Danlos Syndrome (EDS) is a group of hereditary disorders of connective tissue. vEDS is the most severe subtype where patients suffer from life threatening arterial dissections and ruptures, as well as intestinal and uterine ruptures. The average mortality is 51 years of age. An Acer-commissioned patient-finder study phenotypically identified 4,169 vEDS patients in the U.S. from an analysis of a commercially available patient claims database with data of approximately 190 million unique patient lives. Based on that information, Acer estimates the prevalence of phenotypically-defined vEDS in the U.S. could be greater than 1 in 45,000. Currently, there are no FDA-approved therapies for vEDS. Acer is advancing Edsivo (celiprolol), a new chemical entity (NCE), for the treatment of vEDS based on a randomized controlled clinical study of celiprolol(1) and submitted an NDA to the FDA in October 2018. Acer requested priority review for Edsivo which, if granted at the time of potential acceptance of NDA for filing, could result in a Prescription Drug User Free Act (PDUFA) action date of late second quarter 2019. Edsivo received FDA Orphan Drug Designation for the potential treatment of vEDS in 2015.

About Acer Therapeutics

Acer, headquartered in Newton, MA, is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for patients with serious rare and ultra-rare diseases with critical unmet medical need. Acer’s late-stage clinical pipeline includes two candidates for severe genetic disorders: Edsivo (celiprolol) for vascular Ehlers-Danlos syndrome (vEDS), and ACER-001 (a fully taste-masked, immediate release formulation of sodium phenylbutyrate) for urea cycle disorders (UCD) and Maple Syrup Urine Disease (MSUD). There are no FDA-approved drugs for vEDS and MSUD and limited options for UCD, which collectively impact approximately 7,000 patients in the U.S. Acer’s product candidates have clinical proof-of-concept and mechanistic differentiation, and Acer intends to seek approval for them in the U.S. by using the regulatory pathway established under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FFDCA) that allows an applicant to rely at least in part on third-party data for approval, which may expedite the preparation, submission, and approval of a marketing application.

References
(1) Ong KT, et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomized, open, blinded-endpoints trial. Lancet. 2010; 376: 1476–84.

Forward-Looking Statements

This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenues, projected expenses, regulatory approvals, cash position, liquidity, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to expectations regarding our capitalization and resources; the potential for Edsivo™ (celiprolol) and ACER-001 to safely and effectively treat diseases and to be approved for marketing; the commercial or market opportunity in any target indication; the adequacy of our capital to support our future operations and our ability to successfully initiate and complete clinical trials and regulatory submissions; the ability to protect our intellectual property rights; the nature, strategy and our focus; future economic conditions or performance; and the development, expected timeline and commercial potential of any of our product candidates. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources to meet our business objectives and operational requirements, the fact that the results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by our intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. We disclaim any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. You should review additional disclosures we make in our filings with the Securities and Exchange Commission, including our Quarterly Reports on Form 10-Q and our Annual Report on Form 10-K. You may access these documents for no charge at http://www.sec.gov.

Source: Acer Therapeutics Inc.

Posted: October 2018

Edsivo (celiprolol) FDA Approval History

Tagged with:

About author

Related Articles